B
Bull
Bull · 25%ADAG
$1.91
Scenario price
$3.680
-0.208 (-5.64%)At close
Loading chart…
- High
- 3.890
- Open
- 3.890
- VWAP
- 3.74
- Vol
- 123.15K
- Mkt Cap
- 136.22M
- Low
- 3.660
- Amount
- 461.00K
- EV/EBITDA, TTM
- -3.13
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
AI analysis of Adagene Inc. (ADAG)
buyAdagene Inc is a good buy right now due to its significant upside potential. The current price is $3.68, while analysts have set a target price of $9.40, indicating a potential upside of 166.29%. Additionally, the stock has shown a strong year-to-date change of +100.00%, reflecting positive market sentiment despite recent volatility.
Valuation Metrics
The current forward P/E ratio for Adagene Inc. (ADAG) is 0.00, compared to its 5-year average forward P/E of -2.40.
Alphio AI Price Scenarios for ADAG
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ADAG
Events Timeline
News
9.508-12NewsfilterAdagene Reports Mid-Year Financial Results for 2026
6.506-18NASDAQ.COMAnalyst Target Prices Indicate Potential for PGJ
- 7.005-15Newsfilter
Adani Group Resolves U.S. Fraud Charges
- 1.005-12Newsfilter
Adagene to Participate in Investor Meetings
- 9.504-27Newsfilter
Adani Total Gas Reports Q4 Profit Increase Driven by CNG Demand
ADAG FAQ — answered by Alphio AI
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Adagene Inc is a good buy right now due to its significant upside potential. The current price is $3.68, while analysts have set a target price of $9.40, indicating a potential upside of 166.29%. Additionally, the stock has shown a strong year-to-date change of +100.00%, reflecting positive market sentiment despite recent volatility.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.